Kong et al., 2020), opening up novel therapeutic approaches for cardiovascular and metabolic diseases such as atherosclerosis and diabetes
Rather than maxing out a dose, we pull other levers. We might add Cagrilintide , an amylin agonist that synergistically slows gastric emptying, or incorporate MitoQ or SS-31 (Elamipretide) if underlying mitochondrial dysfunction is impairing cellular energy production (ATP)
The results of numerous clinical trials (human) and preclinical trials (animal) suggest that Mucuna pruriens may be effective at treating ED, PD, and diabetes, although additional clinical evidence is still needed
2022b;12(September):1006576
2e lower panels) and mass spectrometry (Supplementary Table 2 and Supplementary Fig
(4)KO group: TPH1 knockout mice were treated i.p with APAP (TPH1, the rate-limiting enzyme for the synthesis of peripheral serotonin)